The Times Australia
Fisher and Paykel Appliances
The Times World News

.

A major ivermectin study has been withdrawn, so what now for the controversial drug?

  • Written by Andrew McLachlan, Head of School and Dean of Pharmacy, University of Sydney
A major ivermectin study has been withdrawn, so what now for the controversial drug?

Ivermectin[1], an existing drug against parasites including head lice, has had a chequered history when it comes to treating COVID-19.

The bulk of studies so far show there’s not enough evidence[2] ivermectin is useful in treating or preventing COVID-19, either alone or with antibiotics or supplements.

Yet interest in the drug remains, on social media, in some countries, with some doctors[3] and with one politician in particular, Liberal MP Craig Kelly, touting its benefits[4].

Now a large clinical trial that seemed to show positive results for ivermectin has been withdrawn[5]. So you’d think that would be end of the ivermectin saga.

But research into ivermectin is ongoing. Here’s what the evidence says so far and what we can expect next.

Read more: How to deal with the Craig Kelly in your life: a guide to tackling coronavirus contrarians[6]

How was ivermectin even a contender?

Ivermectin was identified as a potential COVID-19 treatment based on experiments in isolated cells[7] and animals[8]. The initial lab studies into ivermectin’s effect on the coronavirus involved very high concentrations[9] of the drug. These were many times higher than can be achieved in the body at doses recommended to treat parasites.

As the pandemic progressed, so did ivermectin clinical trials. But when experts who write doctors’ prescribing guidelines reviewed the data, they found not enough evidence to back ivermectin to treat or prevent COVID-19. These groups included Australia’s National COVID-19 Clinical Evidence Taskforce[10] and the World Health Organization[11]. Instead, they said ivermectin should only be used in clinical trials[12].

Read more: Ivermectin is still not a miracle cure for COVID-19, despite what you may have read[13]

The most robust summary of the evidence[14] for ivermectin in COVID-19, published in June, goes one step further. It found available evidence showed ivermectin didn’t work.

This review carefully examined ten higher-quality (randomised-controlled) clinical trials, which involved more than 1,100 patients with COVID-19 being treated with ivermectin.

The researchers excluded many of the low-quality (observational) studies some commentators have used to support ivermectin as a COVID-19 treatment. This was because observational studies cannot control other clinical factors that might influence how people respond to COVID-19, such as other treatments and supportive care.

This major review concluded ivermectin did not reduce death from any cause, the length of stay in hospital or people’s ability to clear the virus. The review also said ivermectin was safe but “not a viable option” to treat COVID-19.

Read more: Head lice drug Ivermectin is being tested as a possible coronavirus treatment, but that's no reason to buy it[15]

But what about the withdrawn study?

In recent months, we heard the seemingly promising results from a large randomised trial[16], which was posted online as a pre-print[17] and had not been independently verified (peer reviewed).

This study stood out because it found ivermectin led to “a substantial improvement and reduction in mortality rate in ivermectin treated groups” — by 90%.

However, the excitement was tempered when the pre-print was withdrawn[18] pending a “formal investigation”. Significant questions were asked[19] about the nature of the primary data on which the study was based and whether some of the paper had been plagiarised, among other issues. This called into question[20] the spectacular positive result for ivermectin.

The trial and publication are still under investigation.

Read more: Stopping, blocking and dampening – how Aussie drugs in the pipeline could treat COVID-19[21]

Surely, that’s the end of ivermectin now?

But the ivermectin story continues. Researchers at the University of Oxford announced in June they would be starting another ivermectin trial[22], called PRINCIPLE[23].

This high-quality trial will involve investigating treatments for people at more risk of serious COVID-19. So far the trial has recruited more than 5,000 volunteers from across the UK. Another part of the trial (into another potential COVID-19 therapy) has already reported results[24].

This new ivermectin trial is just starting and will compare a three-day treatment of ivermectin in people within the first 14 days of COVID-19 symptoms, or having a positive test, with those having usual care. The trial is expected to report its results in the coming months.

What next?

Ivermectin remains a medicine of interest for treating and preventing COVID-19. Yet, key questions remain including the best ivermectin dose, how long ivermectin should be taken and when it should be given to people with COVID based on their stage of infection and illness.

Until then, getting vaccinated[25] will give you the best chance of avoiding severe COVID rather than waiting for a COVID treatment, which may or may not be shown to work.

Read more: How well do COVID vaccines work in the real world?[26]

References

  1. ^ Ivermectin (theconversation.com)
  2. ^ not enough evidence (theconversation.com)
  3. ^ some doctors (www1.racgp.org.au)
  4. ^ touting its benefits (www.sbs.com.au)
  5. ^ withdrawn (www.theguardian.com)
  6. ^ How to deal with the Craig Kelly in your life: a guide to tackling coronavirus contrarians (theconversation.com)
  7. ^ isolated cells (www.sciencedirect.com)
  8. ^ animals (www.biorxiv.org)
  9. ^ very high concentrations (www.ncbi.nlm.nih.gov)
  10. ^ National COVID-19 Clinical Evidence Taskforce (covid19evidence.net.au)
  11. ^ World Health Organization (www.who.int)
  12. ^ clinical trials (app.magicapp.org)
  13. ^ Ivermectin is still not a miracle cure for COVID-19, despite what you may have read (theconversation.com)
  14. ^ most robust summary of the evidence (academic.oup.com)
  15. ^ Head lice drug Ivermectin is being tested as a possible coronavirus treatment, but that's no reason to buy it (theconversation.com)
  16. ^ large randomised trial (www.researchsquare.com)
  17. ^ pre-print (www.thelancet.com)
  18. ^ pre-print was withdrawn (www.theguardian.com)
  19. ^ Significant questions were asked (steamtraen.blogspot.com)
  20. ^ called into question (grftr.news)
  21. ^ Stopping, blocking and dampening – how Aussie drugs in the pipeline could treat COVID-19 (theconversation.com)
  22. ^ another ivermectin trial (www.principletrial.org)
  23. ^ PRINCIPLE (www.principletrial.org)
  24. ^ results (www.principletrial.org)
  25. ^ getting vaccinated (www.mja.com.au)
  26. ^ How well do COVID vaccines work in the real world? (theconversation.com)

Read more https://theconversation.com/a-major-ivermectin-study-has-been-withdrawn-so-what-now-for-the-controversial-drug-164627

Times Magazine

Q&A with Freya Alexander – the young artist transforming co-working spaces into creative galleries

As the current Artist in Residence at Hub Australia, Freya Alexander is bringing colour and creativi...

This Christmas, Give the Navman Gift That Never Stops Giving – Safety

Protect your loved one’s drives with a Navman Dash Cam.  This Christmas don’t just give – prote...

Yoto now available in Kmart and The Memo, bringing screen-free storytelling to Australian families

Yoto, the kids’ audio platform inspiring creativity and imagination around the world, has launched i...

Kool Car Hire

Turn Your Four-Wheeled Showstopper into Profit (and Stardom) Have you ever found yourself stand...

EV ‘charging deserts’ in regional Australia are slowing the shift to clean transport

If you live in a big city, finding a charger for your electric vehicle (EV) isn’t hard. But driv...

How to Reduce Eye Strain When Using an Extra Screen

Many professionals say two screens are better than one. And they're not wrong! A second screen mak...

The Times Features

Q&A with Freya Alexander – the young artist transforming co-working spaces into creative galleries

As the current Artist in Residence at Hub Australia, Freya Alexander is bringing colour and creativi...

Indo-Pacific Strength Through Economic Ties

The defence treaty between Australia and Indonesia faces its most difficult test because of econ...

Understanding Kerbside Valuation: A Practical Guide for Property Owners

When it comes to property transactions, not every situation requires a full, detailed valuation. I...

What’s been happening on the Australian stock market today

What moved, why it moved and what to watch going forward. 📉 Market overview The benchmark S&am...

The NDIS shifts almost $27m a year in mental health costs alone, our new study suggests

The National Disability Insurance Scheme (NDIS) was set up in 2013[1] to help Australians with...

Why Australia Is Ditching “Gym Hop Culture” — And Choosing Fitstop Instead

As Australians rethink what fitness actually means going into the new year, a clear shift is emergin...

Everyday Radiance: Bevilles’ Timeless Take on Versatile Jewellery

There’s an undeniable magic in contrast — the way gold catches the light while silver cools it down...

From The Stage to Spotify, Stanhope singer Alyssa Delpopolo Reveals Her Meteoric Rise

When local singer Alyssa Delpopolo was crowned winner of The Voice last week, the cheers were louder...

How healthy are the hundreds of confectionery options and soft drinks

Walk into any big Australian supermarket and the first thing that hits you isn’t the smell of fr...